A Study of DTC in Patients With AIDS and AIDS Related Complex

M

Merieux Institute

Status

Completed

Conditions

HIV Infections

Treatments

Drug: Ditiocarb sodium

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002069
010A

Details and patient eligibility

About

To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Active opportunistic infection or progressive Kaposi's sarcoma (KS).
  • Dementia.
  • Lymphoma.

Concurrent Medication:

Excluded within 3 weeks of study entry:

Other experimental AIDS therapy.

Patients with the following are excluded:

Active opportunistic infection or progressive Kaposi's sarcoma (KS).

Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems